News

• Kancera has applied for a clinical trial for KAND567

  19 April 2017

• Kancera provides an operational update of the PFKFB3 project

  12 April 2017

• Kancera recruits two PhD students to the EU-funded research programme SYNTRAIN

  6 April 2017

• Kancera completes acquisition of the Fractalkine project for autoimmune diseases and cancer

  4 April 2017

• Kancera comments: Breakthrough for drug development targeting the Fractalkine system that controls immune cells and cancer cells

  28 March 2017

• INTERIM REPORT FOR KANCERA AB (PUBL) Q4 2016. January 1st – December  31st 2016

  21 February 2017

• Kancera provides operational update of the project portfolio

  21 February 2017

• Kancera appoints Joachim Forsgren as Chief Medical Officer

  29 December 2016

• Kancera reports positive results for fractalkine blocker KAN0440567 in preclinical models of pain caused by anti-cancer drugs

  19 December 2016

• Interim Report for Kancera AB (publ) Q3 2016, January 1 – September 30, 2016

  18 November 2016